[ad_1]
A Ena company Respiratory, which develops the INNA-051 product, indicated in a statement that the tests carried out with ferrets, coordinated by vice principal England Public Health, Miles Carroll, showed 96% effectiveness.
The Australian company also indicated that the study, published today on the research portal biomedical bioRxiv provided evidence that the synthetic molecule INNA-051 can be used as a method of preventive antiviral therapy and complementary vaccination programs.
In addition to helping the most vulnerable people, the spray, which would be applied once or twice a week, also prevents people from infected infect other people said Christophe From home, director da Ena Respiratory.
The official also stated that clinical evidence of substancia it will take place in the next four months.
The company indicated that it obtained seven million euros from investors The Australians continue their research pending the completion of toxicity studies and obtaining the appropriate legal permits.
Always be the first to know.
Follow the chosen site for the fourth consecutive year Consumer Choice.
Download our free app.
[ad_2]
